NASDAQ:HSGX - Histogenics Stock Price, Forecast & News

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

Histogenics Corp (NASDAQ:HSGX) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.10. View Histogenics' Earnings History.

Histogenics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Histogenics.

News articles about HSGX stock have been trending somewhat negative recently, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Histogenics earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Histogenics.

Some companies that are related to Histogenics include Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Bionik Laboratories (BNKL), NanoVibronix (NAOV), Rewalk Robotics (RWLK), Allied Healthcare Products (AHPI), Precision Therapeutics (POAI), Ocugen (OCGN) and Avitar (AVTI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Diagnostics Group (IDXG), Verastem (VSTM), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Ocular Therapeutix (OCUL), Synergy Pharmaceuticals (SGYP), Trevena (TRVN) and Opko Health (OPK).

(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HSGX stock can currently be purchased for approximately $0.52.

Histogenics has a market capitalization of $48.91 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Histogenics employs 49 workers across the globe.View Additional Information About Histogenics.

The official website for Histogenics is http://www.histogenics.com/.

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]